| Recruiting | Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer NCT06900647 | Sun Yat-sen University | Phase 1 |
| Recruiting | A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurre NCT06369285 | Puma Biotechnology, Inc. | Phase 2 |
| Recruiting | A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients. NCT06202118 | Alpha Tau Medical LTD. | N/A |
| Unknown | Reoperative Sentinel Lymph Node Biopsy in Patients With Recurrent Ipsilateral Breast Cancer NCT06329089 | Hospital Clinic of Barcelona | — |
| Terminated | A Biomarker Screening Protocol for Participants With Solid Tumors NCT05891197 | Lyell Immunopharma, Inc. | — |
| Recruiting | A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Brea NCT06202261 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | A Study to Investigate LYL797 in Adults With Solid Tumors NCT05274451 | Lyell Immunopharma, Inc. | Phase 1 |
| Active Not Recruiting | ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer NCT06570031 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer NCT04360941 | Royal Marsden NHS Foundation Trust | Phase 1 |
| Completed | B002 in Patients With HER2-positive Breast Cancer NCT04382352 | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1 |
| Completed | ModraDoc006/r in Patients With Breast Cancer NCT03890744 | Modra Pharmaceuticals | Phase 2 |
| Completed | T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer NCT03530696 | University of Arizona | Phase 2 |
| Unknown | Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer NCT03750396 | Gangnam Severance Hospital | Phase 2 |
| Completed | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Ge NCT03602079 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Unknown | Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing NCT03475979 | Seoul National University Hospital | — |
| Completed | Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer NCT02843126 | Fuda Cancer Hospital, Guangzhou | Phase 1 / Phase 2 |
| Terminated | 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer NCT02624700 | Virginia Commonwealth University | Phase 2 |
| Completed | Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III NCT02203552 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants NCT02390427 | Otto Metzger, MD | Phase 1 |
| Active Not Recruiting | Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patien NCT02226276 | City of Hope Medical Center | N/A |
| Terminated | Phase II Study of Everolimus Beyond Progression NCT02269670 | Emory University | Phase 2 |
| Terminated | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kid NCT02273752 | Emory University | Phase 2 |
| Completed | Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metast NCT02015559 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Withdrawn | Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liv NCT01741597 | City of Hope Medical Center | Phase 1 |
| Completed | BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx NCT02038010 | Northwestern University | Phase 1 |
| Terminated | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer NCT01938833 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Completed | Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Pos NCT02060253 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing NCT01953588 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Completed | Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca NCT02041429 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Terminated | PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer NCT01712815 | University of Southern California | N/A |
| Terminated | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection NCT01249443 | AIDS Malignancy Consortium | Phase 1 |
| Completed | Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breas NCT01986569 | Asan Medical Center | Phase 3 |
| Completed | Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or R NCT02046421 | University of Chicago | Phase 1 |
| Completed | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabin NCT01881230 | Celgene | Phase 2 / Phase 3 |
| Completed | Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid NCT01987726 | Ohio State University Comprehensive Cancer Center | — |
| Terminated | GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast NCT01918306 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Terminated | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive NCT01873833 | University of Southern California | Phase 2 |
| Active Not Recruiting | Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With NCT01730833 | City of Hope Medical Center | Phase 2 |
| Terminated | Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Bre NCT01868503 | Stanford University | Phase 2 |
| Completed | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer Wi NCT01783756 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) NCT01824836 | ECOG-ACRIN Cancer Research Group | N/A |
| Completed | Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer NCT01876238 | Case Comprehensive Cancer Center | N/A |
| Active Not Recruiting | BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer NCT01791478 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Completed | Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy NCT01819233 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | N/A |
| Completed | Cabergoline in Metastatic Breast Cancer NCT01730729 | Northwestern University | EARLY_Phase 1 |
| Terminated | Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer NCT01729884 | University of Washington | Phase 2 |
| Withdrawn | A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases NCT01939483 | University of California, Irvine | N/A |
| Completed | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy NCT01720602 | University of Washington | N/A |
| Completed | Phase I: At-Home Support for Rural Women Using Group Video Calling NCT01672684 | Stanford University | Phase 1 |
| Terminated | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Meta NCT01705340 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery NCT01483196 | Wake Forest University Health Sciences | N/A |
| Completed | BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Ca NCT01339442 | Washington University School of Medicine | Phase 1 |
| Completed | Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer NCT01493310 | University of Chicago | Phase 1 |
| Completed | Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastroz NCT01478477 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases NCT01421017 | NYU Langone Health | Phase 1 / Phase 2 |
| Terminated | Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer NCT01394211 | University of Arizona | Phase 2 |
| Completed | Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER NCT01355393 | University of Washington | Phase 1 / Phase 2 |
| Completed | Circulating miRNAs. NCT01722851 | Cancer Trials Ireland | — |
| Completed | Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases Fr NCT00992602 | University of Washington | Phase 2 |
| Unknown | A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer NCT01351597 | Korean Breast Cancer Study Group | Phase 2 |
| Completed | Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer NCT01385280 | University of Arizona | N/A |
| Withdrawn | Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast Cancer NCT01729832 | Ohio State University Comprehensive Cancer Center | N/A |
| Withdrawn | Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By NCT01292083 | University of Southern California | N/A |
| Completed | Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer NCT01288261 | University of Arizona | Phase 1 |
| Terminated | Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and NCT01276054 | University of Southern California | Phase 2 |
| Terminated | Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Recei NCT01243541 | Northwestern University | N/A |
| Completed | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy NCT01153672 | University of Washington | N/A |
| Completed | Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tu NCT01245205 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer NCT01764789 | Ohio State University Comprehensive Cancer Center | N/A |
| Terminated | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors NCT01233505 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer NCT01147484 | NCIC Clinical Trials Group | Phase 2 |
| Terminated | Endoscopic Breast Surgery in Treating Patients With Breast Cancer NCT01222377 | University of Southern California | N/A |
| Completed | Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast NCT01104259 | University of Washington | Phase 1 |
| Terminated | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, o NCT01151449 | National Cancer Institute (NCI) | Phase 2 |
| Completed | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors NCT01158274 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Completed | Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer NCT01084057 | City of Hope Medical Center | Phase 1 |
| Completed | Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy NCT01487954 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer NCT01009983 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Ca NCT01051401 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer NCT01042535 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer NCT01037790 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer NCT01706432 | University of Chicago | — |
| Unknown | A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Ca NCT00912639 | Korean Breast Cancer Study Group | Phase 4 |
| Completed | Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Rela NCT01013337 | Abramson Cancer Center at Penn Medicine | N/A |
| Completed | Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer NCT00821964 | University of Washington | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage IV Breast Cancer NCT00791037 | University of Washington | Phase 1 / Phase 2 |
| Completed | F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormon NCT00602043 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer NCT00733408 | University of Washington | Phase 2 |
| Completed | Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting NCT00618657 | University of California, Irvine | Phase 2 |
| Completed | Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By S NCT00559507 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Brea NCT00577122 | Indiana University | Phase 2 |
| Completed | Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer NCT00509587 | National Cancer Institute (NCI) | Phase 2 |
| Completed | VEGF Trap in Treating Patients With Metastatic Breast Cancer NCT00369655 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole NCT00416715 | University of Washington | Phase 2 |
| Completed | Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer NCT00258349 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery NCT00348699 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1) NCT00307229 | Ontario Clinical Oncology Group (OCOG) | Phase 1 |
| Completed | Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breas NCT00331552 | University of Washington | Phase 1 / Phase 2 |
| Completed | Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer NCT00182767 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer NCT00096109 | National Cancer Institute (NCI) | Phase 2 |
| Completed | ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment NCT00425672 | University of Washington | Phase 1 / Phase 2 |
| Completed | A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) NCT00244881 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer NCT00217399 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer NCT00132002 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer NCT00077376 | National Cancer Institute (NCI) | Phase 2 |
| Completed | FR901228 in Treating Patients With Metastatic Breast Cancer NCT00098397 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer NCT00095888 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases NCT00098605 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib in Treating Patients With Metastatic Breast Cancer NCT00096434 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer NCT00077363 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer NCT00082810 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer NCT00079326 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vaccine Therapy in Treating Patients With Metastatic Breast Cancer NCT00071942 | National Cancer Institute (NCI) | Phase 1 |
| Completed | GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer NCT00068588 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cance NCT00057941 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer NCT00159458 | University of Southern California | Phase 2 |
| Completed | Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Tre NCT00228358 | University of Washington | Phase 1 |
| Completed | Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer NCT00054028 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer NCT00045188 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer NCT00055861 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer NCT00039455 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer NCT00024154 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Decitabine in Treating Patients With Advanced Solid Tumors NCT00030615 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors NCT00028535 | National Cancer Institute (NCI) | Phase 1 |
| Completed | PS-341 in Treating Women With Metastatic Breast Cancer NCT00025584 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer NCT00017394 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer NCT00004888 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer NCT00006228 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer NCT00005817 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is In NCT00003440 | National Cancer Institute (NCI) | Phase 3 |
| Withdrawn | Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory NCT00003536 | Burzynski Research Institute | Phase 2 |
| Withdrawn | Antineoplaston Therapy in Treating Women With Advanced Breast Cancer NCT00003455 | Burzynski Research Institute | Phase 2 |
| Withdrawn | Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer NCT00053339 | Alliance for Clinical Trials in Oncology | Phase 3 |